Investigation Report on Trastuzumab in China, 2018-2022

  • ID: 4583736
  • Report
  • Region: China
  • 30 Pages
  • China Research & Intelligence
1 of 5

Trastuzumab was developed by GENENTECH and approved in Sept. 1998 by the FDA for clinical use. Its trade name is Herceptin and it is now a major product of Roche. In 2017, trastuzumab was sold for around USD 7 billion worldwide. It is a standard medicine recommended by the international medical community for HER2 positive breast cancer and gastric cancer.

In 2002, trastuzumab entered the Chinese market and was mainly used to treat HER2 metastatic breast cancer. After entering China, trastuzumab developed rapidly. Its annual sales increased from less than CNY 70 million in 2007 to CNY 887 million in 2017, and the CAGR reached 30.4% during 2007 to 2017. Before 2017, trastuzumab was produced by GENENTECH and Roche. Since 2017, it has been monopolized by the latter in the Chinese market. Currently, Roche is the single product in the market

Trastuzumab was first approved to market by the FDA in Sept. 1998 and was admitted to China in 2002. The patent for trastuzumab in the EU expired in Jul. 2014 and will expire in the U.S. in Jun. 2019. Many pharmaceutical companies have taken part in the research and development of biosimilar drugs. Three biomedical companies, Fuhong Hanlin, Anke Bio and Jiahe Bio, are now producing biosimilar of Trastuzumab in clinical Phase III. According to the approval requirements of CDE, Fuhong Hanlin and Anke Bio are expected to be the first to hold licenses. Fuhong Hanlin is even ahead of the other and is expected to get sales permits in 2019, which makes it the first case of domestic biosimilar of trastuzumab.

In Jul. 2017, Trastuzumab was incorporated in China's National Health Insurance Directory, which caused a surge in market demand and shortages in many parts of the country. In Jun. 2018, the CFDA issued a notice to allow Trastuzumab be sold on market when being inspected through ports, which can save 2 to 3 months.

CRI expects that from 2018 to 2020 Roche's Herceptin will continue to monopolize the Chinese market. In 2020, domestic trastuzumab will be successively launched and grab market shares at a low price. Besides, the incidence of breast cancer and gastric diseases in China keeps rising, so the demand for trastuzumab will also continue to increase.

Topics Covered

  • Development environment of Trastuzumab
  • Development of Trastuzumab in China
  • Chinese Market Size of Trastuzumab
  • Sale Price of Trastuzumab in China
  • Competition Landscape of Trastuzumab in China
  • Prospects of Chinese trastuzumab market
READ MORE
Note: Product cover images may vary from those shown
2 of 5

1 Trastuzumab-related Concepts
1.1 Indication
1.2 Development of Trastuzumab in China

2 Chinese Market Overview of Trastuzumab
2.1 Patents and Government Approval on Drugs
2.2 Major Manufacturers
2.3 Analysis of Potential Entrants

3 Sales of Trastuzumab in China, 2013-2017
3.1 Sales Value of Trastuzumab
3.1.1 Overall Sales Value
3.1.2 Sales Value in Different Regions
3.2 Sales Volume of Trastuzumab
3.2.1 Overall Sales Volume
3.2.2 Sales Volume in Trastuzumab Different Regions
3.3 Market Share of Trastuzumab in Different Dosage Forms
3.3.1 Market Share of Trastuzumab Dosage Forms by Sales Value
3.3.2 Market Share of Trastuzumab Dosage Forms by Sales Volume

4 Market Share of Trastuzumab Manufacturers in China, 2013-2017
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Major Manufacturers and Reference Sales Price of Trastuzumab in Chinese Market, 2017-2018
5.1 GENENTECH
5.2 Shanghai Roche Pharmaceuticals Ltd.

6 Prospects of Chinese Trastuzumab Market, 2018-2022
6.1 Forecast on Market Size
6.2 Forecast on Market Trend

Part of Charts
Chart Sales Value of Trastuzumab in China, 2013-2017
Chart Sales Value of Trastuzumab in Different Regions, 2017
Chart Sales Volume of Trastuzumab in China, 2013-2017
Chart Sales Value and Market Share of Shanghai Roche's Trastuzumab in China, 2013-2017
Chart Sales Value and Market Share of GENENTECH's Trastuzumab in China, 2013-2017
Chart Sales Value and Market Share of Trastuzumab Injections in China, 2013-2017
Chart Sale Price of GENENTECH's Trastuzumab in Several Chinese Cities, 2017
Chart Forecast on Sales Value of Trastuzumab in China, 2018-2022

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • GENENTECH
  • Shanghai Roche Pharmaceuticals Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll